QTTB

Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity in autoimmune and inflammatory diseases.

The share price is falling and falling. The company has decided to discontinue the development of ADX-097, previously considered its main value driver, in favor of concentrating on bempikibart for the treatment of patients with alopecia areata (AA). source: investing

Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases, in a Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases. source: company press release

Q32 Bio Inc expected to post a loss of $1.51 a share source: tradingview